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Abstract
Purpose Benign prostatic hyperplasia (BPH) is a progres-
sive disease that is commonly associated with bothersome
lower urinary tract symptoms (LUTS) and might result in
complications, such as acute urinary retention and BPH-
related surgery. Therefore, the goals of therapy for BPH are
not only to improve LUTS in terms of symptoms and uri-
nary Xow, but also to identify those patients at a risk of
unfavorable disease progression and to optimize their man-
agement. This article reviews the current status of therapy
with 5-reductase inhibitors (5ARIs), namely Wasteride and
dutasteride, for men with LUTS and BPH.
Method Data from key randomized controlled trials
(Oxford level 1b) on the use of 5ARIs are analyzed.
Results The eYcacy of 5ARIs either as monotherapy or in
combination with 1-adrenoceptor antagonists in the man-
agement of LUTS and the impact of monotherapy and com-
bined therapy on BPH progression are discussed. Further
promises, including the withdrawal of the -blocker from
the combined medical treatment and the potential clinical
implications from the use of 5ARIs for prostate cancer che-
moprevention in patients receiving 5ARIs for symptomatic
BPH are highlighted.
Conclusions  Current evidence shows that 5ARIs are
eVective in treating LUTS and preventing disease progres-
sion and represent a recommended option in treatment
guidelines for men who have moderate to severe LUTS and
enlarged prostates.
Keywords Benign prostatic hyperplasia · Lower urinary 
tract symptoms · 5-Reductase inhibitors · Dutasteride · 
Finasteride · Combination treatment · Disease progression · 
Chemoprevention
Introduction
Lower urinary tract symptoms (LUTS) are very common in
aging men and women. There is an increasing understanding
that male LUTS result from several pathophysiological condi-
tions, but benign prostatic hyperplasia (BPH) has been recog-
nized as a major contributing factor for LUTS in aging men. It
is also known that LUTS aVect quality of life in the majority
of those who reach average life expectancy [1]. In addition,
longitudinal population-based studies which best analyse natu-
ral history of the disease have shown that BPH is a progressive
disease. Progression includes increase of symptoms, acute uri-
nary retention (AUR), and the need for BPH-related surgery
[1, 2]. Therefore, it becomes evident that BPH-LUTS has sig-
niWcant economical implications, since an increasing number
of elderly men will eventually seek help for this condition. In
daily practice, therapeutic approach is usually initiated with
medical treatment and, if drugs fail, minimally invasive inter-
ventions or other surgical procedures will follow.
First-line pharmacologic treatment options for men with
moderate to severe LUTS include the 1-adrenoceptor
antagonist alfuzosin, doxazosin, tamsulosin, or terazosin
and the 5-reductase inhibitor (5ARI) Wnasteride or
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dutasteride. This article focuses on the role of 5ARIs in the
management of LUTS and disease progression.
Mechanism of action
Normal and abnormal growth of the prostate is dependent on
the presence of hormones and growth factors. The androgen
dihydrotestosterone (DHT) which is converted in the cell
from its precursor testosterone by the enzyme 5-reductase, a
nuclear-bound steroid enzyme localized primarily in pros-
tatic stromal cells, is crucial in the initial development and
normal growth of the prostate [3]. Two isoforms of 5ARIs
have been identiWed: type 1 with minor expression and activ-
ity in the prostate, but predominant activity in extraprostatic
tissues, such as skin or liver, and type 2 with predominant
expression and activity in the prostate [4]. Both 5ARI isoen-
zymes are expressed in normal prostatic tissue, but over-
expressed in BPH where they are responsible for the
hyperplasia of stromal and epithelial cells in the transition
zone and periurethral glands of the prostate that is associated
with prostate gland enlargement, while in prostate cancer
(PCa) cells 5AR1 expression is increased and 5AR2 expres-
sion is decreased compared with BPH tissue [5, 6]. Further-
more, both 5aR1 and 5aR2 are more prevalent in high-grade
when compared with low-grade PCa [7]. 5ARIs act by apop-
tosis of prostatic epithelial cells, thereby reducing prostate
size by an average of 15–25% over time [5, 8, 9].
Although dutasteride and Wnasteride are both 5ARIs,
their pharmacologic and clinical proWles are diVerent.
Table 1 displays the main characteristics of 5ARIs. Clark
et al. directly compared the two 5ARIs and found that
dutasteride achieved a greater reduction in serum DHT con-
centration (94.7%) compared with Wnasteride (70.8%) [10].
There is no direct comparative study with regard to intra-
prostatic DHT concentration, but the reported suppression
appears to be slightly better for dutasteride than Wnasteride
(94–97 vs. 85–91%) [11].
EYcacy in terms of International Prostate Symptom 
Score (IPSS) and peak urinary Xow rate (Qmax)
Monotherapy
Finasteride is the most extensively studied 5ARI. Boyle
et al. performed a meta-analysis of six randomized, pla-
cebo-controlled clinical trials [12]. The most signiWcant
Wnding was a positive correlation between mean baseline
prostate volume and mean change in symptom score or
Qmax. Symptoms decreased by 1.8 points on the Quasi-
International Prostate Symptom Score (IPSS) Scale and
Qmax increased by 0.9 ml/s in men with prostate
volumes < 20 ml compared with 2.8 points and 1.8 ml/s for
men with prostate volumes > 60 ml [12]. The diVerence
between  Wnasteride and placebo becomes signiWcant for
men, with a baseline prostate volume of > 40 ml. Following
this meta-analysis, the outcomes of the 4-year Proscar
Long-term EYcacy and Safety Study (PLESS) were
released [13]. Finasteride reduced prostate volume by 18%
compared with an increase of 14% with placebo, improved
symptom scores (3.3 points vs. 1.3 for placebo) and
increased Qmax (1.9 vs. 0.2 ml/s for placebo) [13].
The combined analysis of the AUA-BPH Guidelines
Panel found that Wnasteride leads to an IPSS improvement
of 3.4 points at 12 months in both randomized placebo-
controlled and open-label extension studies [14]. Symptom
improvement is durable for up to 6 years in patients who
maintained treatment. In addition, Wnasteride achieves a
sustained  Qmax improvement of approximately 2 ml/s.
In most trials, 5ARIs are slightly less eVective than
-blockers.
More recently, data from the monotherapy arm of the
Medical Therapy of Prostatic Symptoms (MTOPS) study
showed that prostate volume decreased by a median of 19%
in patients receiving Wnasteride when compared with 24%
increase in those receiving placebo [15]. SigniWcant
improvements over time in the IPSS and Qmax occurred in
all monotherapy groups compared with the placebo group.
The clinical eYcacy of dutasteride was evaluated in the
three pivotal, 2-year, randomized, double-blind, placebo-
controlled phase III trials [16]. Pooled analysis of these
studies included 4,325 men and showed that dutasteride
achieved a 4.5-point IPSS reduction resulting in a net diVer-
ence of 2.2 points compared with placebo. Qmax improved
signiWcantly in the dutasteride group from 1 month, with an
increase of 2.2 ml/s reported at 24 months (compared with
0.6 in the placebo group). A 26% reduction in prostate
volume relative to placebo was found, with signiWcant
reductions from 1 month after treatment initiation and
continuation until study end-point at 2 years. Following the
completion of the blinded phase, 2,340 men entered the
open-label, 24-months extension trial [17]. Dutasteride
Table 1 Key pharmacokinetic and pharmacodynamic characteristics
of 5-reductase inhibitors
Tmax time of peak serum concentration, T½ elimination half time,
DHT dihydrotestosterone
Parameters Dutasteride Finasteride
5-Reductase inhibition target Type 1 and 2 Type 2
Metabolized in Liver Liver
Recommended daily dosage (mg) 1 £ 0.5 1 £ 5.0
Oral bioavailability (%) 60 80
Tmax (h) 1–3 2
T½ 5 Weeks 6–8 h
Bound to plasma proteins (%) 99.5 90
Serum DHT suppression (%) 94.7 70.8World J Urol (2010) 28:9–15 11
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further reduced IPSS signiWcantly; at the end of the 48-
month trial, IPSS was reduced by 6.5 points in men who
received dutasteride during the entire study period and by
5.6 points in men who were initially treated with placebo
and later with dutasteride. In contrast to previous Wndings
with  Wnasteride, there was no diVerence in the eYcacy
between prostate volumes 30–39 and ¸ 40 ml.
In a 12-month, randomized, comparative study, the
Enlarged Prostate International Comparator Study (EPICS),
1,630 patients older than 50 years were randomized to
dutasteride (n = 813) or Wnasteride (n = 817) [18]. After
1 year of treatment, prostate volume reduction from baseline
was similar in both groups at 27.4%. Improvements in IPSS
(6.2 vs. 5.8) and Qmax (2.1 vs. 1.8 ml/s) were greater for
dutasteride than Wnasteride, but not statistically signiWcant.
Combination therapy
It is reasonable to assume that the combination of a 5ARI
and  -blocker, which have diVerent and complementary
modes of action, would potentially maximize treatment
response. However, the Wrst randomized, placebo-con-
trolled trials with a follow-up · 12 months did not report
superiority of combination treatment. Both the PRospective
European DoxazosIn and Combination Therapy (PRE-
DICT) trial (using doxazosin and/or Wnasteride) and the
Veterans AVairs Cooperative Studies Benign Prostatic
Hyperplasia Study (using terazosin and/or Wnasteride)
showed that combination therapy was superior to 5ARI
monotherapy, but failed to demonstrate a signiWcant beneWt
over -blocker monotherapy [19, 20]. The MTOPS Study
with a follow-up of > 4 years was conducted to address the
question of long-term beneWt [15]. Although it was
designed as a progression trial, MTOPS demonstrated that
long-term combination therapy is superior to either -blocker
or 5ARI monotherapy in improving LUTS and Qmax. The 4-
year mean reduction in IPSS was 4.9, 6.6, 5.6, and 7.4 in the
placebo, doxazosin, Wnasteride, and combination therapy
groups, respectively. Similarly, the mean improvement in
Qmax was 2.8, 4.0, 3.2, and 5.1 ml/s, respectively. IPSS
decrease and Qmax increase in either active treatment was sig-
niWcantly better than placebo, doxazosin was signiWcantly
better than Wnasteride, and combination treatment was sig-
niWcantly better than either monotherapy.
The Combination of Avodart and Tamsulosin (Com-
bAT) trial compared the eYcacy of dutasteride and tamsul-
osin alone with the eYcacy of combination therapy in men
with larger prostates (> 30 ml) and higher serum PSA con-
centrations (1.5–10 g/l) [21]. However, the trial did not
have a placebo arm. In the pre-planned 2-year analysis, the
combination treatment provided a signiWcantly greater
improvement in symptoms than either monotherapy alone
[21]. At 2 years, the mean decrease from baseline IPSS was
6.2 with combination therapy, 4.9 with dutasteride, and 4.3
with tamsulosin. A statistically signiWcant diVerence was
achieved for combination therapy over dutasteride alone
from month 3 and over tamsulosin alone from month 9. A
combination therapy was also signiWcantly more eVective
than either monotherapy in improving Qmax at month 6
throughout month 24. The adjusted mean Qmax increase in
the combination group was 2.4 ml/s and signiWcantly
greater than for dutasteride and tamsulosin (1.9 and 0.9 ml/
s, respectively). The adjusted mean decrease from baseline
prostate volume was 26.9% in the combination therapy
group and 28.0% in the dutasteride group but unchanged
for tamsulosin-treated patients.
Post hoc analyses of 2-year data from the CombAT
study provided useful insights into the impact of several
baseline parameters on changes of IPSS and Qmax [22]. It
was found that combination therapy was more eVective
than tamsulosin or dutasteride monotherapy alone in
improving IPSS and Qmax after 2 years regardless of base-
line parameters [22]. When compared with tamsulosin,
dutasteride showed greater IPSS improvement in certain
subgroups, most notably in those men with values higher
than the median: IPSS > 16, prostate volume > 49 ml,
PSA > 3.5 g/l, and IPSS-QoL score ¸ 4. In addition,
dutasteride alone or in combination was associated with
signiWcantly greater improvements in Qmax compared with
tamsulosin.
The 4-year data of the CombAT study has been pub-
lished recently [23]. For patients who completed the study
period, mean change in IPSS from baseline to year 4 was
signiWcantly higher for the combination therapy compared
with tamsulosin or dutasteride alone (¡7.3,  ¡4.9,  ¡6.4,
respectively). Decrease in IPSS-QoL score was signiW-
cantly greater for the combination treatment (¡1.5) com-
pared with tamsulosin (¡1.1) or dutasteride (¡1.3). Qmax
improvement was signiWcantly higher for combination
treatment (2.4 ml/s) compared with tamsulosin (0.7 ml/s) or
dutasteride (2 ml/s). There was a tendency towards a con-
tinuous decrease in IPSS and continuous increase in Qmax
for dutasteride monotherapy and combination treatment
over time, whereas both parameters worsened again during
tamsulosin treatment after 15–18 months. Interestingly,
postvoid residual urine signiWcantly decreased in the treat-
ment arms containing dutasteride, but not with tamsulosin
alone. Table 2 displays the key RCTs with 5ARIs.
EYcacy in terms of disease progression
Monotherapy
The goal of BPH therapy is not only to improve LUTS, but
also prevent disease progression. Analysis of the placebo12 World J Urol (2010) 28:9–15
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arm (737 men) of the MTOPS study showed that the rate of
overall clinical progression of BPH events in the placebo
group was 4.5 per 100 person-years, for a cumulative inci-
dence of 17% among men who had follow-up data of at
least 4 years [15]. Several risks factors at baseline were
identiWed for disease progression, such as prostate
volume ¸ 31 ml, PSA concentration ¸ 1.6 g/l,  Qmax ·
10.6 ml/s, postvoid residual volume ¸ 39 ml, and age ¸
62 years. Risk reduction is mediated through decrease in
prostate volume and possibly through decrease in bladder
outlet resistance. In the PLESS study after 4 years, Wnaste-
ride treatment reduced the relative risk of AUR by 57%
(AUR occurred in 7% of men receiving placebo and 3%
receiving  Wnasteride) and surgery by 55% (10% of men
receiving placebo and 5% receiving Wnasteride) [13]. In the
MTOPS study, a signiWcant reduction in the risk of overall
clinical progression (deWned as IPSS increase ¸ 4 points,
AUR, urinary incontinence, renal insuYciency, or recurrent
urinary tract infections) by 34% in the Wnasteride arm com-
pared with placebo (to 2.9 per 100 person-years) was
shown [15]. An earlier pooled analysis of randomized trials
with 2-year follow-up data clearly indicated that the treat-
ment with Wnasteride signiWcantly decreased the occurrence
of AUR by 57% and surgical intervention by 34% with an
overall 35% reduction in the two BPH-related endpoints
relative to placebo in patients with moderately symptomatic
BPH [24].
Dutasteride has also demonstrated eYcacy in reducing
the risks for AUR and BPH-related surgery. Pooled phase
III studies have shown a reduced relative risk of AUR
(57%) and a surgical intervention (48%) compared with
placebo at 2 years [16]. In addition, this reduction was
maintained to 4 years during the open-label phase of the
study [23, 25].
Combination therapy
The impact of combination treatment on BPH progression
has also been evaluated from the MTOPS trial that included
3,047 men treated for an average of 4.5 years. This land-
mark study showed that the risk of long-term clinical pro-
gression (primarily due to increasing IPSS) was reduced by
66% with combined therapy (vs. placebo) and to a greater
extent than with either Wnasteride or doxazosin monotherapy
(34 and 39%, respectively) [15]. When only the risks of
AUR and need for BPH-related surgery over the 4-year
Table 2 Key randomized trials with 5-reductase inhibitors in men with benign prostatic enlargement and LUTS
Qmax maximum urinary Xow rate, PV prostate volume, AUR acute urinary retention, RR risk reduction vs. placebo, NA not assessed
a Pooled data
b Median values
c SigniWcant compared with placebo
d SigniWcant compared with -blocker






















Andersen et al. [24]a 24 Placebo 2,109 1b
Finasteride 2,113 NA NA NA ¡34c ¡57c
McConnell et al. [13] 48 Placebo 1,503 ¡1.3 +0.2 +14.0 1b
Finasteride 1,513 ¡3.3c +1.9c ¡18.0c ¡55c ¡57c
McConnell et al. [15]b 54 Placebo 737 ¡4.0 1.4 +24.0 1b
Doxazosin 756 ¡6.0c 2.5c +24.0 ¡3 ¡35
Finasteride 768 ¡5.0c 2.2c ¡19.0c,d ¡64c,d ¡68c,d
Combination 786 ¡7.0c,d,e 3.7c,d,e ¡19.0c,d ¡67c,d ¡81c,d
Roehrborn et al. [16]a 24 Placebo 2,158 ¡2.3 0.6 +1.5 1b
Dutasteride 2,167 ¡4.5c 2.2c ¡25.7c ¡48c ¡57c
Roehrborn et al. [21] 24 Tamsulosin 1,611 ¡4.3 0.9 0.0 1b
Dutasteride 1,623 ¡4.9 1.9 ¡28.0 NA NA
Combination 1,610 ¡6.2d,e 2.4d,e ¡26.9d NA NA
Roehrborn et al. [23] 48 Tamsulosin 1,611 ¡3.8 0.7 +4.6 1b
Dutasteride 1,623 ¡5.3 2.0 ¡28.0d ¡31.1d ¡18.3d
Combination 1,610 ¡6.3d,e 2.4d,e ¡27.3d ¡70.6d ¡67.6dWorld J Urol (2010) 28:9–15 13
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study were analyzed, Wnasteride, alone or in combination,
but not doxazosin signiWcantly reduced both risks. Rates of
AUR were 0.2 events/100 person-years in the Wnasteride
group, 0.1 events/100 person-years in the combination ther-
apy group, 0.4 events/100 person-years in the doxazosin
group, and 0.6 events/100 person-years in the placebo
group. In terms of risk for invasive BPH therapy, the pla-
cebo group experienced 1.3 events/100 person-years com-
pared to 0.5 events/100 person-years with Wnasteride, 0.4
events/100 person-years with combination therapy, and 1.3
events/100 person-years with doxazosin. Subsequent analy-
sis of the MTOPS data concluded that men with prostate
volumes of 25 ml or more have a greater beneWt from com-
bination therapy in terms of reducing risk of long-term clin-
ical progression compared with either monotherapy [26].
In the CombAT trial, entry thresholds for prostate vol-
ume (¸ 30 ml) and PSA serum concentration (¸ 1.5 g/l)
have been used to select patients with higher risk of disease
progression [21]. The predeWned 4-year primary endpoints
were reduction in the risks of AUR and BPH-related sur-
gery [23]. BPH overall disease progression (deWned as
symptom deterioration ¸ 4 IPSS points, AUR, inconti-
nence, recurrent urinary tract infections, or renal insuY-
ciency) appeared after 4 years in 12.6% of patients with the
combination of dutasteride and tamsulosin, but in 17.8%
with dutasteride, and in 21.5% with tamsulosin. The reduc-
tion in the relative risk of overall disease progression was
signiWcantly greater for the combination treatment (¡31.2%
compared to dutasteride and ¡44.1% compared to tamsulo-
sin). When compared with tamsulosin, combination therapy
reduced the relative risks of AUR by 67.8%, BPH-related
surgery by 70.6% and symptom deterioration by 41.3%
after 4 years.
Discontinuation therapy
5ARIs need several months to develop clinical eYcacy,
whereas -blockers act within hours or a couple of days;
therefore, many clinicians initially use -blockers for fast
symptom relief until eYcacy of 5ARIs is achieved. The
randomized, double-blind, placebo-controlled Symptom
Management After Reducing Therapy (SMART) trial eval-
uated the combination of tamsulosin with dutasteride and
the impact of tamsulosin discontinuation after 6 months
[27]. After discontinuation of the -blocker, almost three
quarters of patients reported no worsening of symptoms.
However, patients with severe symptoms (IPSS ¸ 20) at
baseline may beneWt from longer combination therapy.
A recent prospective open-label multicentre trial evalu-
ated the equivalence of the eYcacy and safety of combina-
tion therapy (Wnasteride plus -blocker) for 9 months,
followed by monotherapy with Wnasteride alone for 3 or
9 months [28]. Equivalence was deWned as mean diVerence
of · 2 IPSS points between the end of the combination
period and the end of each monotherapy period. LUTS
improvement after combination therapy was sustained for
3 months (IPSS diVerence 1.24) and 9 months (IPSS diVer-
ence ¡0.44) with a similar safety proWle. The main limita-
tions of such studies include the short duration of the
combination therapy and the short follow-up period.
In a retrospective study using a large managed care
member database, the likelihood of -blocker discontinuation
was evaluated over a 12-month period in 1,674 patients
aged ¸ 65 years receiving -blockers in combination therapy
with either dutasteride or Wnasteride [29]. Dutasteride
patients discontinued -blocker therapy 64% faster than
Wnasteride patients at any time point. At 12 months, 62% of
patients were treated with dutasteride alone compared to
43.7% of men treated with Wnasteride alone. Despite its limi-
tations regarding the retrospective nature and the subjective
decision of -blocker cessation, this study has shown a diVer-
ence in rate and timing in favor of dutasteride which may
have clinical implications requiring further examination.
Safety-adverse events
5ARIs are well tolerated and have only minimal side
eVects. The most common adverse events (AE) are sexual
dysfunction including, reduced libido, erectile dysfunction
and, less frequently, ejaculation disorders which occur
more frequently in recipients with 5ARIs than with placebo
[5, 9]. Gynecomastia appears in approximately 1–2% of
patients. The new onset of most drug-related AEs usually
arises within the Wrst year of treatment, and new-onset AE
rates after the Wrst year are often similar to those among
patients receiving placebo. It seems that drug-related sexual
dysfunction do not represent a clinically signiWcant cause
of treatment withdrawal [5, 9].
It has also been reported that dutasteride and Wnasteride
have a similar safety proWle. In a 1-year comparative trial in
men who received either dutasteride (n = 813) or Wnasteride
(n = 817), the incidence of impotence (7 vs. 8%), decreased
libido (5 vs. 6%), ejaculation disorders (1% in both
groups), gynecomastia (1% in both groups), headache (1%
in both groups), and malaise/fatigue (1% in both groups)
did not diVer signiWcantly [30]. In both COMBAT and
MTOPS, drug-related AEs were more frequent during com-
bination treatment than for either monotherapy [15, 21, 23].
5ARIs and PSA
Serum PSA concentration is used as a proxy parameter for
prostate volume and marker for PCa. In most clinical14 World J Urol (2010) 28:9–15
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guidelines, PSA evaluation is recommended during initial
evaluation of patients with LUTS [14, 31]. A higher PSA
value is a good predictor for the risk of AUR and need for
surgery in men with BPH-LUTS [15, 32].
Dihydrotestosterone, the predominant factor of exocrine
secretion of prostatic epithelial cells, is the main source of
intraprostatic and serum PSA. The use of 5ARIs results in
serum PSA decrease of about 50% after 6–12 months [33,
34]. Therefore, PSA concentration has to be doubled for
counseling and clinical decision making in men receiving
5ARIs. Marks et al. performed an extensive review of
available studies and concluded that doubling of serum
PSA concentration in men who have received 5ARIs for up
to 6–9 months overestimated actual PSA, whereas correctly
estimated actual PSA concentration during 1–3 years of
treatment and underestimating it thereafter [34]. It was pro-
posed that a PSA increase ¸ 0.3 g/l from a nadir should
be used as an additional biopsy trigger in men receiving a
5ARIs for BPH; these men should also be followed-up on a
regular base.
5ARIs and chemoprevention
There is an increasing interest in the use of 5ARIs for PCa
chemoprevention. The American Society of Clinical Oncol-
ogy (ASCO) and American Urological Association Practice
Guidelines Committee jointly convened a panel of experts
to develop evidence-based recommendations [35]. Although
this issue is beyond the scope of this article, some Wndings
may have clinical implications in patients receiving 5ARIs
for symptomatic BPH. Data from the Prostate Cancer
Prevention Trial (PCPT), currently the only completed
randomized PCa risk reduction trial, showed a 24.8%
reduction in PCa prevalence during the 7-year period
between the Wnasteride (18.4%) and the placebo group
(24.4%) [36]. However, a higher incidence of high-grade
cancers (Gleason scores 7–10) was found in the Wnasteride
arm (37 vs. 22.2% for placebo). Several potential explana-
tions have been proposed and the majority of the panel
members judged that the higher incidence of high-grade
tumors is likely due to confounding factors than to an actual
increase in aggressive cancers [35]. However, men taking
5ARIs for the management of BPH-LUTS may also beneWt
from chemoprevention. In such cases, observed beneWts
must be weighed against theoretical harm in men who are
being treated for symptomatic or bothersome conditions.
New information are eagerly expected from the REduction
by DUtasteride of prostate Cancer Events (REDUCE) trial,
an ongoing 4-year, multicentre, randomized, double-blind,
placebo-controlled study aiming at the evaluation of the
eYcacy and safety of oral dutasteride 0.5 mg/day in PCa
risk reduction [37].
Conclusions
Current evidence shows that monotherapy with 5ARIs is
eVective in men with BPH-LUTS and benign prostatic
enlargement by altering the underlying disease process; in
addition, 5ARIs provide the long-term beneWt of risk reduc-
tion for disease progression. For this reason, both the Euro-
pean and the American Urological Association Guidelines
recommend 5ARIs in the management of patients with
LUTS associated with demonstrable prostatic enlargement
[14, 31]. The MTOPS study demonstrated the long-term
superiority of combination treatment to either monotherapy
with regard to both symptom reduction and disease pro-
gression, while the analysis of the CombAT study, for the
Wrst time, has shown beneWt in improving symptoms and
Qmax for combination therapy over monotherapies during
the  Wrst 12 months of treatment, thereby reinforcing the
position of 5ARIs in the management of patients with
BPH-LUTS.
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